Randomized controlled trials have established the clinical efficacy and safety of infliximab in treating fistulizing Crohn disease (CD), and while evidence for adalimumab and vedolizumab in this indication is weaker, these drugs are also used in clinical practice, sometimes in treatment sequences of biologics, to treat fistulizing CD. In Europe, where access to biologic drugs is largely driven by budgetary considerations, biosimilars have the potential to improve access to treatment.
Randomized controlled trials have established the clinical efficacy and safety of infliximab in treating fistulizing Crohn disease (CD), and while evidence for adalimumab and vedolizumab in this indication is weaker, these drugs are also used in clinical practice, sometimes in treatment sequences of biologics, to treat fistulizing CD. In Europe, where access to biologic drugs is largely driven by budgetary considerations, biosimilars have the potential to improve access to treatment.
Authors of a study published in the United European Gastroenterology Journal developed a Markov model to compare the treatment sequences of 1, 2, and 3 biologic drugs, from the payer’s perspective, on a 5-year time horizon, with data on effectiveness and health state utilities obtained from the published literature. Country-specific costs (in Belgium, France, Germany, Hungary, Italy, the Netherlands, Spain, Sweden, and the United Kingdom), and both official list prices and estimated real prices for the drugs, were taken into consideration.
When considering the use of single biologics at list price versus standard (non-biologic) treatment:
In treatment sequences involving 2 to 3 biologics, based on list price, adding a second biologic to the treatment sequence after biosimilar infliximab provided additional QALY gains (0.103—0.133) compared to the biosimilar infliximab alone, but at larger additional costs (€6129–€18,700, or approximately $7588-$23,150), with adalimumab being more cost-effective than vedolizumab as a second agent. Adding a third agent (vedolizumab) to biosimilar infliximab and adalimumab provided additional QALY gains (0.113-0.120) at larger additional costs (€10,444-€17,587, or approximately $12,929-$21,772) in most countries.
When considering a real price at a 30% discount to the list price of infliximab and biosimilar infliximab—and a 20% decrease for adalimumab—in each country, the researchers observed a 19% to 30% decrease in the ICERs for biosimilar infliximab (€24,364-€56,086, or approximately $30,162-$69,433) per QALY compared with standard care. The ICER of the biosimilar infliximab—adalimumab treatment sequence decreased by 20% to 22% (€45,513-€105,875, or approximately $56,344-$131,070) per QALY.
The authors conclude that the first choice of biologic treatment for fistulizing CD should be biosimilar infliximab. In the case of treatment failure, a switch to adalimumab or vedolizumab would provide meaningful health benefits, but at increased costs.
Reference
Baji P, Gulácsi L, Brodszky V, et al. Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United European Gastroenterol J. 2018;6(2):310-321. doi: 10.1177/2050640617708952.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.